NCT07092566View on ClinicalTrials.gov

R.E.C.K vs Exparel in Robotic Nephrectomy

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2027

Conditions
Renal CarcinomaNephrectomy / MethodsPain Management
Interventions
DRUG

Ropivacaine HCL

123 mg, intramuscular

DRUG

Exparel

100 mL total dose - Intramuscular (IM), intraoperatively

DRUG

Epinephrine

0.25 mg, intramuscular

DRUG

Clonidine HCL

0.04 mg, intramuscular

DRUG

Ketorolac

15 mg, intramuscular

Trial Locations (1)

28204

Levine Cancer, Charlotte

All Listed Sponsors
collaborator

Atrium Health Levine Cancer Institute

OTHER

lead

Wake Forest University Health Sciences

OTHER